[go: up one dir, main page]

NO2023003I1 - valoctocogene roxaparvovec in all forms as protected by the basic patent - Google Patents

valoctocogene roxaparvovec in all forms as protected by the basic patent

Info

Publication number
NO2023003I1
NO2023003I1 NO2023003C NO2023003C NO2023003I1 NO 2023003 I1 NO2023003 I1 NO 2023003I1 NO 2023003 C NO2023003 C NO 2023003C NO 2023003 C NO2023003 C NO 2023003C NO 2023003 I1 NO2023003 I1 NO 2023003I1
Authority
NO
Norway
Prior art keywords
valoctocogene
roxaparvovec
protected
forms
basic patent
Prior art date
Application number
NO2023003C
Other languages
English (en)
Original Assignee
Univ London
Biomarin Pharm Inc
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51585244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2023003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ London, Biomarin Pharm Inc, St Jude Childrens Res Hospital filed Critical Univ London
Publication of NO2023003I1 publication Critical patent/NO2023003I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO2023003C 2013-09-12 2023-01-12 valoctocogene roxaparvovec in all forms as protected by the basic patent NO2023003I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877042P 2013-09-12 2013-09-12

Publications (1)

Publication Number Publication Date
NO2023003I1 true NO2023003I1 (no) 2023-01-12

Family

ID=51585244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2023003C NO2023003I1 (no) 2013-09-12 2023-01-12 valoctocogene roxaparvovec in all forms as protected by the basic patent

Country Status (34)

Country Link
US (6) US9504762B2 (no)
EP (2) EP3044231B1 (no)
JP (5) JP6735672B2 (no)
KR (2) KR20230006058A (no)
CN (2) CN112538501A (no)
AR (1) AR097657A1 (no)
AU (1) AU2014318890B2 (no)
CA (3) CA3178379A1 (no)
CL (1) CL2016000502A1 (no)
CY (2) CY1124213T1 (no)
DK (1) DK3044231T3 (no)
ES (1) ES2813698T3 (no)
FI (1) FIC20230007I1 (no)
FR (1) FR23C1007I2 (no)
HR (1) HRP20201324T1 (no)
HU (2) HUE050484T2 (no)
IL (2) IL244404B (no)
LT (2) LT3044231T (no)
LU (1) LUC00298I2 (no)
MX (2) MX386802B (no)
NL (1) NL301222I2 (no)
NO (1) NO2023003I1 (no)
NZ (1) NZ716549A (no)
PE (1) PE20160769A1 (no)
PH (1) PH12016500328A1 (no)
PL (1) PL3044231T3 (no)
PT (1) PT3044231T (no)
RS (1) RS61039B1 (no)
RU (1) RU2710307C2 (no)
SG (1) SG11201601932UA (no)
SI (1) SI3044231T1 (no)
SM (1) SMT202000458T1 (no)
TW (1) TWI632239B (no)
WO (1) WO2015038625A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
LT3044231T (lt) 2013-09-12 2020-11-10 Biomarin Pharmaceutical Inc. Aav vektoriai, apimantys viii faktorių koduojantį geną
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3626274B1 (en) * 2015-04-16 2025-01-22 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
PE20181338A1 (es) 2015-09-24 2018-08-21 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
KR102766526B1 (ko) * 2015-10-28 2025-02-13 상가모 테라퓨틱스, 인코포레이티드 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
BR112018009732A8 (pt) 2015-11-13 2019-02-26 Baxalta GmbH ?polinucleotídeo, vetor de vírus adeno-associado, partícula de vírus adeno-associado, célula hospedeira, métodos para produzir uma partícula de vírus adeno-associado, para tratar hemofilia a, para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado?
SG10202106307UA (en) * 2015-11-13 2021-07-29 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2017180857A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
AU2017269371B2 (en) 2016-05-25 2021-08-05 Lonza Houston Inc. Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt
EP3491008A2 (en) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2020001402A (es) * 2017-08-01 2021-01-29 Spark Therapeutics Inc Metodos de terapia genica del factor viii (fviii).
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CA3100000A1 (en) 2018-05-14 2019-11-21 Biomarin Pharmaceutical Inc. Stable expression of aav vectors in juvenile subjects
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
JP2021530524A (ja) 2018-07-16 2021-11-11 バクスアルタ インコーポレイテッド 発現が増強された組換えｆｖｉｉｉ変異体をコードするウイルスベクターを使用する血友病ａの遺伝子療法
WO2020020475A1 (en) * 2018-07-27 2020-01-30 Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles
KR20210039428A (ko) 2018-08-03 2021-04-09 상가모 테라퓨틱스, 인코포레이티드 인자 viii의 발현에 의한 개선된 임상 파라미터
CN113227385B (zh) 2018-08-09 2024-12-24 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CA3116283A1 (en) * 2018-10-12 2020-04-16 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
CA3133255A1 (en) * 2019-03-13 2020-09-17 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing fviii therapeutics
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
JP6831943B1 (ja) 2019-10-24 2021-02-17 三ツ星ベルト株式会社 摩擦伝動ベルトおよびその製造方法
WO2021084275A1 (en) * 2019-11-01 2021-05-06 Freeline Therapeutics Limited Factor viii polypeptide
CN114829391A (zh) * 2019-11-14 2022-07-29 生物马林药物股份有限公司 用肝特异性基因疗法载体治疗遗传性血管性水肿
CA3159985A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
EP4237545A1 (en) 2020-11-02 2023-09-06 BioMarin Pharmaceutical Inc. Process for enriching adeno-associated virus
WO2022119839A1 (en) * 2020-12-01 2022-06-09 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
CA3204462A1 (en) * 2020-12-18 2022-06-23 Sangamo Therapeutics, Inc. Improved pharmaceutical compositions containing adeno-associated viral vector
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2023002483A (ja) * 2021-06-22 2023-01-10 ファイザー・インク 昆虫細胞におけるアデノ随伴ウイルスベクターの産生
EP4377466A4 (en) * 2021-07-28 2025-11-05 Biomarin Pharm Inc LARGE-SCALE ADENE-ASSOCIATED VIRUS PRODUCTION SYSTEMS
MX2024002334A (es) * 2021-08-23 2024-05-23 Bioverativ Therapeutics Inc Genes optimizados del factor viii.
WO2023036054A2 (en) * 2021-09-08 2023-03-16 Inspirar Limited Composition and method for treating hemophilia
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
TW202400796A (zh) * 2022-03-11 2024-01-01 美商同源醫藥公司 雙向雙重啟動子表現載體及其用途
EP4511055A2 (en) * 2022-04-20 2025-02-26 AskBio Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
UY40442A (es) 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
KR20250108100A (ko) 2022-09-22 2025-07-15 디나코 아게 Aav 유전자 치료법 벡터를 이용한 심근병증의 치료
CN115948408A (zh) * 2022-09-23 2023-04-11 上海信致医药科技有限公司 改进的人凝血因子viii基因表达盒及其应用
WO2024074143A1 (en) * 2022-10-08 2024-04-11 Lingyi Biotech Co., Ltd. Construct for enhancing gene expression
CN116555266B (zh) * 2023-06-09 2024-11-12 呈诺再生医学科技(北京)有限公司 肝脏特异性表达的重组启动子和载体及其在肝脏相关疾病治疗中的应用
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors
CN118064436B (zh) * 2024-04-18 2024-07-26 上海凌医生物科技有限公司 一种增强基因表达的嵌合启动子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
AU7264694A (en) * 1993-07-13 1995-02-13 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
JP2001500376A (ja) 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
WO2000011149A1 (en) * 1998-08-24 2000-03-02 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
CN1286981C (zh) * 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US7943374B2 (en) * 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
DK2768521T3 (en) * 2011-10-18 2016-10-24 Csl Behring Gmbh Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII
CN103215308B (zh) * 2013-02-01 2015-12-23 中国科学院苏州生物医学工程技术研究所 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
LT3044231T (lt) 2013-09-12 2020-11-10 Biomarin Pharmaceutical Inc. Aav vektoriai, apimantys viii faktorių koduojantį geną

Also Published As

Publication number Publication date
JP2025113388A (ja) 2025-08-01
IL244404A0 (en) 2016-04-21
MX386802B (es) 2025-03-19
US20250332224A1 (en) 2025-10-30
WO2015038625A1 (en) 2015-03-19
NL301222I2 (nl) 2023-10-19
CL2016000502A1 (es) 2016-10-21
US10463718B2 (en) 2019-11-05
FR23C1007I1 (fr) 2023-03-24
IL244404B (en) 2021-10-31
JP2019193675A (ja) 2019-11-07
BR112016005576A2 (pt) 2017-09-12
HUE050484T2 (hu) 2020-12-28
US20170095538A1 (en) 2017-04-06
FIC20230007I1 (fi) 2023-02-08
AU2014318890B2 (en) 2019-03-07
US20220339262A1 (en) 2022-10-27
CA3178384A1 (en) 2015-03-19
US20150071883A1 (en) 2015-03-12
EP3044231B1 (en) 2020-08-05
CY2023006I1 (el) 2023-06-09
LTPA2023508I1 (no) 2023-04-11
LT3044231T (lt) 2020-11-10
JP6735672B2 (ja) 2020-08-05
SG11201601932UA (en) 2016-04-28
PL3044231T3 (pl) 2021-01-11
JP7523211B2 (ja) 2024-07-26
CN105636981A (zh) 2016-06-01
CN105636981B (zh) 2020-11-06
AR097657A1 (es) 2016-04-06
NL301222I1 (no) 2023-03-01
KR102484396B1 (ko) 2023-01-04
TW201546285A (zh) 2015-12-16
JP2023133597A (ja) 2023-09-22
MX2016003262A (es) 2016-09-29
IL286859A (en) 2021-10-31
RU2016113702A (ru) 2017-10-17
BR112016005576A8 (pt) 2022-10-18
RU2019141647A (ru) 2020-01-27
RS61039B1 (sr) 2020-12-31
US11406690B2 (en) 2022-08-09
KR20160049015A (ko) 2016-05-04
HUS2300003I1 (hu) 2023-01-28
PH12016500328A1 (en) 2016-05-02
EP3044231A1 (en) 2016-07-20
EP3770169A1 (en) 2021-01-27
SMT202000458T1 (it) 2020-11-10
ES2813698T8 (es) 2022-01-26
JP2016534739A (ja) 2016-11-10
LTC3044231I2 (no) 2025-04-10
PT3044231T (pt) 2020-08-27
CA2921232C (en) 2023-03-14
HRP20201324T1 (hr) 2020-11-27
PE20160769A1 (es) 2016-08-12
TWI632239B (zh) 2018-08-11
CN112538501A (zh) 2021-03-23
HK1226416A1 (en) 2017-09-29
US20200101140A1 (en) 2020-04-02
US12239692B2 (en) 2025-03-04
MX2021012014A (es) 2021-10-22
US9504762B2 (en) 2016-11-29
CA3178379A1 (en) 2015-03-19
CA2921232A1 (en) 2015-03-19
DK3044231T3 (da) 2020-09-07
JP2021072871A (ja) 2021-05-13
LUC00298I2 (no) 2025-09-22
ES2813698T3 (es) 2021-03-24
NZ716549A (en) 2022-10-28
CY2023006I2 (el) 2023-11-15
CY1124213T1 (el) 2022-03-24
KR20230006058A (ko) 2023-01-10
AU2014318890A1 (en) 2016-02-25
RU2710307C2 (ru) 2019-12-26
FR23C1007I2 (fr) 2024-06-14
SI3044231T1 (sl) 2020-12-31
US20180161403A1 (en) 2018-06-14
RU2019141647A3 (no) 2020-05-18

Similar Documents

Publication Publication Date Title
NO2023003I1 (no) valoctocogene roxaparvovec in all forms as protected by the basic patent
FIC20240034I1 (fi) Dasiglukagoni kaikissa peruspatentin suojaamissa muodoissa
NO2023021I1 (no) Loncastuximab tesirine in all forms protected by the basic patent
FIC20250023I1 (fi) Latsertinibi kaikissa peruspatentin suojaamissa muodoissa
FIC20250031I1 (fi) Datopotamabi-derukstekaani
NL301278I2 (nl) vadadustat
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
UY4298S (es) Carcasa
EP2989885A4 (en) HARVESTER
EP2889350A4 (en) ADHESIVE COMPOSITION
EP2975063A4 (en) LOW SUBSTITUTED CELLULOSE ACETATE
DK3027750T3 (da) Biokatalytisk sammensætning
EP2991647A4 (en) DEUTERED AMLEXANOX
DK3071227T3 (da) Fiskevaccine
CL2014000652S1 (es) Trituradora
CL2014000653S1 (es) Trituradora
FI10138U1 (fi) Kelkkateltta
UA26734S (uk) Барна стійка
UA26629S (uk) Барна стійка
DK3082855T3 (da) Sammensætning
ES1092430Y (es) "Anafe paellero"
UA28834S (uk) Болт
UA28835S (uk) Болт
UA28801S (uk) Болт